Interferon Sciences plans to study Alferon N for MS, is in clinicals for HIV.
Executive Summary
INTERFERON SCIENCES WILL TEST INTERFERON ALFA-N3 FOR MULTIPLE SCLEROSIS "once sufficient funding has been obtained," the New Brunswick, N.J.-based biotech reported in its recently-released 1994 annual report. Interferon Sciences, Inc. cited "significant adverse reactions" with Chiron/Berlex' Betaseron for relapsing-remitting multiple sclerosis as a factor in the decision to study its natural-source, human leukocyte-derived alpha interferon for the disease. ISI is the only manufacturer of natural source alpha interferon in the U.S.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth